What is the current valuation of the Oral Anti-Diabetic Drug Market?

The Oral Anti-Diabetic Drug Market was valued at 109.6 USD Billion in 2024. Read More

What is the projected market valuation for the Oral Anti-Diabetic Drug Market in 2035?

The market is projected to reach 150.1 USD Billion by 2035. Read More

What is the expected CAGR for the Oral Anti-Diabetic Drug Market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 2.9%. Read More

Which drug classes dominate the Oral Anti-Diabetic Drug Market?

The leading drug classes include Biguanides, Sulfonylureas, and SGLT2 Inhibitors, with valuations ranging from 24.6 to 40.1 USD Billion. Read More

How do branded and generic prescriptions compare in the Oral Anti-Diabetic Drug Market?

Generic prescriptions are projected to generate between 60.0 and 80.0 USD Billion, while branded prescriptions are expected to reach 49.6 to 70.1 USD Billion. Read More

What are the key patient types targeted in the Oral Anti-Diabetic Drug Market?

The market primarily targets Type 2 Diabetes patients, with a projected valuation of 80.0 to 110.0 USD Billion. Read More

Who are the major players in the Oral Anti-Diabetic Drug Market?

Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, and Merck & Co., among others. Read More

What is the market performance of DPP-4 Inhibitors in the Oral Anti-Diabetic Drug Market?

DPP-4 Inhibitors are expected to generate between 20.0 and 25.0 USD Billion. Read More

What is the market potential for Insulin Secretagogues in the Oral Anti-Diabetic Drug Market?

Insulin Secretagogues are projected to achieve a valuation of 35.0 to 45.0 USD Billion. Read More

How does the market for Prediabetes compare to Type 1 and Type 2 Diabetes?

The Prediabetes segment is expected to reach 19.6 to 28.1 USD Billion, significantly lower than the Type 2 Diabetes segment. Read More

How fast is the Global Oral Anti-Diabetic Drug Market expected to grow between 2025 and 2035?

The market is expected to grow at a CAGR of 2.21% between 2025 and 2035. Read More

What is the projected market size of the Global Oral Anti-Diabetic Drug Market by 2035?

By 2035, the Global Oral Anti-Diabetic Drug Market is projected to reach a value of 105.0 USD Billion. Read More

Which region is expected to dominate the Global Oral Anti-Diabetic Drug Market in 2024?

North America is expected to dominate the market with a valuation of 35.1 USD Billion in 2024. Read More

What is the expected market value for the Global Oral Anti-Diabetic Drug Market in Europe in 2024?

In 2024, the market value for the Global Oral Anti-Diabetic Drug Market in Europe is expected to be 25.0 USD Billion. Read More

What is the market size for Biguanides within the Global Oral Anti-Diabetic Drug Market in 2024?

Biguanides are expected to have a market size of 36.77 USD Billion in 2024. Read More

Which major players are leading the Global Oral Anti-Diabetic Drug Market?

Key players in the market include Novo Nordisk, Amgen, Johnson & Johnson, Merck & Co, and Pfizer. Read More

What is the market value for SGLT2 Inhibitors in 2024?

The market value for SGLT2 Inhibitors is estimated to be 6.62 USD Billion in 2024. Read More

What is the expected market growth for the APAC region by 2035?

The APAC region is expected to reach a market size of 20.2 USD Billion by 2035. Read More

How much is the market for Sulfonylureas expected to grow by 2035?

The market for Sulfonylureas is expected to grow to 24.3 USD Billion by 2035. Read More

Oral Anti-Diabetic Drug Market

Oral Anti-Diabetic Drug Market Research Report By Drug Class (Biguanides, Sulfonylureas, Thiazolidinediones, DPP-4 Inhibitors, SGLT2 Inhibitors), By Action Mechanism (Insulin Sensitizers, Insulin Secretagogues, Alpha-Glucosidase Inhibitors, Renal Glucose Reabsorption Inhibitors), By Prescription Type (Generic, Branded), By Patient Type (Type 1 Diabetes, Type 2 Diabetes, Prediabetes) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

2.9%

2024 Market Size

$ 109.6 Billion

2035 Market Size

$ 150.1 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/40608-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
  1. 4.1.1 Biguanides | |
  2. 4.1.2 Sulfonylureas | |
  3. 4.1.3 Thiazolidinediones | |
  4. 4.1.4 DPP-4 Inhibitors | |
  5. 4.1.5 SGLT2 Inhibitors |
2. 4.2 Healthcare, BY Action Mechanism (USD Billion) | |
  1. 4.2.1 Insulin Sensitizers | |
  2. 4.2.2 Insulin Secretagogues | |
  3. 4.2.3 Alpha-Glucosidase Inhibitors | |
  4. 4.2.4 Renal Glucose Reabsorption Inhibitors |
3. 4.3 Healthcare, BY Prescription Type (USD Billion) | |
  1. 4.3.1 Generic | |
  2. 4.3.2 Branded |
4. 4.4 Healthcare, BY Patient Type (USD Billion) | |
  1. 4.4.1 Type 1 Diabetes | |
  2. 4.4.2 Type 2 Diabetes | |
  3. 4.4.3 Prediabetes |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Novo Nordisk (DK) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Sanofi (FR) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Merck & Co. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Johnson & Johnson (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Eli Lilly and Company (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GlaxoSmithKline (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Takeda Pharmaceutical Company (JP) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
7. 6.4 US MARKET ANALYSIS BY ACTION MECHANISM |
8. 6.5 US MARKET ANALYSIS BY PRESCRIPTION TYPE |
9. 6.6 US MARKET ANALYSIS BY PATIENT TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS |
11. 6.8 CANADA MARKET ANALYSIS BY ACTION MECHANISM |
12. 6.9 CANADA MARKET ANALYSIS BY PRESCRIPTION TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS |
16. 6.13 GERMANY MARKET ANALYSIS BY ACTION MECHANISM |
17. 6.14 GERMANY MARKET ANALYSIS BY PRESCRIPTION TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE |
19. 6.16 UK MARKET ANALYSIS BY DRUG CLASS |
20. 6.17 UK MARKET ANALYSIS BY ACTION MECHANISM |
21. 6.18 UK MARKET ANALYSIS BY PRESCRIPTION TYPE |
22. 6.19 UK MARKET ANALYSIS BY PATIENT TYPE |
23. 6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS |
24. 6.21 FRANCE MARKET ANALYSIS BY ACTION MECHANISM |
25. 6.22 FRANCE MARKET ANALYSIS BY PRESCRIPTION TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE |
27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
28. 6.25 RUSSIA MARKET ANALYSIS BY ACTION MECHANISM |
29. 6.26 RUSSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE |
31. 6.28 ITALY MARKET ANALYSIS BY DRUG CLASS |
32. 6.29 ITALY MARKET ANALYSIS BY ACTION MECHANISM |
33. 6.30 ITALY MARKET ANALYSIS BY PRESCRIPTION TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE |
35. 6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS |
36. 6.33 SPAIN MARKET ANALYSIS BY ACTION MECHANISM |
37. 6.34 SPAIN MARKET ANALYSIS BY PRESCRIPTION TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ACTION MECHANISM |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PRESCRIPTION TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY DRUG CLASS |
45. 6.42 CHINA MARKET ANALYSIS BY ACTION MECHANISM |
46. 6.43 CHINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE |
48. 6.45 INDIA MARKET ANALYSIS BY DRUG CLASS |
49. 6.46 INDIA MARKET ANALYSIS BY ACTION MECHANISM |
50. 6.47 INDIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE |
52. 6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS |
53. 6.50 JAPAN MARKET ANALYSIS BY ACTION MECHANISM |
54. 6.51 JAPAN MARKET ANALYSIS BY PRESCRIPTION TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ACTION MECHANISM |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PRESCRIPTION TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
61. 6.58 MALAYSIA MARKET ANALYSIS BY ACTION MECHANISM |
62. 6.59 MALAYSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE |
64. 6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS |
65. 6.62 THAILAND MARKET ANALYSIS BY ACTION MECHANISM |
66. 6.63 THAILAND MARKET ANALYSIS BY PRESCRIPTION TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE |
68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
69. 6.66 INDONESIA MARKET ANALYSIS BY ACTION MECHANISM |
70. 6.67 INDONESIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
73. 6.70 REST OF APAC MARKET ANALYSIS BY ACTION MECHANISM |
74. 6.71 REST OF APAC MARKET ANALYSIS BY PRESCRIPTION TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
78. 6.75 BRAZIL MARKET ANALYSIS BY ACTION MECHANISM |
79. 6.76 BRAZIL MARKET ANALYSIS BY PRESCRIPTION TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE |
81. 6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS |
82. 6.79 MEXICO MARKET ANALYSIS BY ACTION MECHANISM |
83. 6.80 MEXICO MARKET ANALYSIS BY PRESCRIPTION TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
86. 6.83 ARGENTINA MARKET ANALYSIS BY ACTION MECHANISM |
87. 6.84 ARGENTINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ACTION MECHANISM |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ACTION MECHANISM |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PRESCRIPTION TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ACTION MECHANISM |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
103. 6.100 REST OF MEA MARKET ANALYSIS BY ACTION MECHANISM |
104. 6.101 REST OF MEA MARKET ANALYSIS BY PRESCRIPTION TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY ACTION MECHANISM, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY ACTION MECHANISM, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Oral Anti-Diabetic Drug Market Segmentation

Oral Anti-Diabetic Drug Market By Drug Class (USD Billion, 2025-2035)

Biguanides
Sulfonylureas
Thiazolidinediones
DPP-4 Inhibitors
SGLT2 Inhibitors

Oral Anti-Diabetic Drug Market By Action Mechanism (USD Billion, 2025-2035)

Insulin Sensitizers
Insulin Secretagogues
Alpha-Glucosidase Inhibitors
Renal Glucose Reabsorption Inhibitors

Oral Anti-Diabetic Drug Market By Prescription Type (USD Billion, 2025-2035)

Generic
Branded

Oral Anti-Diabetic Drug Market By Patient Type (USD Billion, 2025-2035)

Type 1 Diabetes
Type 2 Diabetes
Prediabetes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”